Chong Kun Dang Pharmaceutical

At a glance

Chong Kun Dang Pharmaceutical filed 77 disclosures in the last 12 months, including 22 5% holder, 8 insider and 4 earnings. The most recent key filing was on Oct 30: Operating profit ₩23.7B, up 15.4% YoY. Revenue ₩431B, up 0.8% YoY.

Revenue for 2025 was ₩1.69T, up 6.7% on 2024. Operating margin was 4.8% against 6.3% a year earlier. Debt was 79% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩926B and operating profit of ₩32.7B.

The 2025 annual report lists 2,304 employees with an average tenure of 10 years and average pay of ₩79.6M, #382 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩211M each on average. It paid ₩500 per common share in cash dividends, against ₩1,100 a year earlier (-54.5%). (주)종근당홀딩스 and related parties held 39.74% at year end.

Of 2 recent 5%+ holder reports, 1 raised and 1 cut a stake; the largest stake reported was 40.15% on Oct 8.

From the 2025 annual report

Staff: 2,304 (1,569 men, 735 women), of whom 91 on fixed-term contracts. Total pay for the year: ₩186B. Directors and auditors: 8, paid ₩1.7B in total.

Dividends (common shares)

Largest shareholder

(주)종근당홀딩스 holds 26.29%; with 5 related parties the group holds 39.74% of common shares at year end (from 39.19% at the start of the year).

Individuals paid ₩500M or more

Auditor: 안진회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports